Search Results - "AlShehry, Nawal Faiez"

  • Showing 1 - 10 results of 10
Refine Results
  1. 1
  2. 2

    Phase 2 Study of 5 Days Azacytidine Priming Prior to Fludarabine, Cytarabine and G-CSF Combination for Patients with Relapsed or Refractory AML by Motabi, Ibraheem H., Iqbal, Shahid, Zaidi, Syed Ziauddin A., Albtoosh, Belal, Alshehry, Nawal Faiez, AlGhamdi, Mubarak S., Tailor, Imran Khan, Altaf, Syed

    Published in Blood (29-11-2018)
    “…Background: Acute Myeloid Leukemia (AML) is a group of heterogeneous clonal disorder of myeloid progenitor cells. Relapsed and refractory AML represent a…”
    Get full text
    Journal Article
  3. 3
  4. 4
  5. 5

    Doublet Versus Triplet PET: Is END of Therapy PET Needed IF Interim PET Is Negative in Hodgkin'S or Diffuse Large B CELL Lymphoma? by Tailor, Imran K, Btoosh, Bilal, Hamdy, Shaimaa, Raja, Shanker, Alharbi, Mohammed O, Motabi, Ibraheem H, Alshehry, Nawal Faiez, Qureshi, Mohammed S, AlGhamdi, Mubarak S., Zaidi, Syed Ziauddin A.

    Published in Blood (02-12-2016)
    “…Introduction: Baseline (PETb) and end of therapy (PETe) FDG PET is standard of care in the management of hodgkin's lymphoma (HL) and diffuse large B cell…”
    Get full text
    Journal Article
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10